Shots:

• Sanofi reported the data from the P-III (HERCULES) trial assessing the efficacy and safety of tolebrutinib (oral) vs PBO in patients with nrSPMS
• The study met its 1EP by delaying the onset of confirmed disability progression (CDP) in nrSPMS patients. The 1EP outcome was defined as a 6-mons. CDP, indicated by an increase of ≥1.0 point from the baseline EDSS score when it was ≤5.0 or an increase of ≥0.5 point when it was >5.0
• The company expects to present the data from HERCULES and GEMINI 1 and 2 evaluating tolebrutinib at the ECTRIMS on 20th Sep

Ref: Sanofi | Image: Sanofi

Related News: Sanofi Pauses Patient Enrollment in P-III Studies of Tolebrutinib for the Treatment of Multiple Sclerosis and Myasthenia Gravis in the US 
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com